07.01.2013 Views

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

FBUS<br />

91115<br />

BUAUC<br />

83188<br />

increase in IgG titer between acute and convalescent sera<br />

confirms recent or current infection.<br />

<strong>Test</strong> Performed by: Focus Diagnostics<br />

5785 Corporate Avenue<br />

Cypress, CA 90630-4750<br />

Buspirone (Buspar)<br />

Reference Values:<br />

Therapeutic and toxic ranges have not been established.<br />

Expected serum buspirone concentrations in patients taking<br />

recommended daily dosages: up to 10.00 ng/mL.<br />

<strong>Test</strong> performed by: Medtox <strong>Laboratories</strong>, Inc.<br />

402 W. County Road D<br />

St. Paul, MN 55112<br />

Busulfan, Intravenous Dose, Area Under the Curve (AUC),<br />

Plasma<br />

Clinical Information: Busulfan is an alkylating agent used to ablate bone marrow cells before<br />

hematopoietic stem cell transplant.(1) Busulfan is typically administered in intravenous (IV) doses of 0.8<br />

mg/kg once every 6 hours over 4 days, a total of 16 doses. Dose-limiting toxicity of busulfan is hepatic<br />

veno-occlusive disease. To avoid toxicity while ensuring busulfan dose adequacy to completely ablate the<br />

bone marrow, IV dosing should be guided by pharmacokinetic (PK) evaluation of area under the curve<br />

(AUC) and clearance after the first dose.(2) The PK evaluation should be carried out at the end of the first<br />

dose, with results of PK testing available to facilitate dose adjustment before beginning the fifth dose.<br />

Useful For: Guiding dosage adjustments to achieve complete bone marrow ablation while minimizing<br />

dose-dependent toxicity<br />

Interpretation: This test should only be ordered when the following criteria are met: -Busulfan dosing<br />

protocol must be intravenous (IV) administration of 8 mg/kg doses every 6 hours over 4 days, for a total<br />

of 16 doses -Specimens must be drawn as described below: - 1 specimen drawn immediately after<br />

termination of a 2-hour IV infusion of busulfan - 1 specimen drawn 1 hour after the infusion is terminated<br />

- 1 specimen drawn 2 hours after the infusion is terminated - 1 specimen drawn 4 hours after the infusion<br />

is terminated These results will be used to calculate a 6-hour area under the curve (AUC). If a different<br />

dosing or specimen collection protocol is used, or if different calculations are required, please contact the<br />

Laboratory Director. The optimal result for AUC (6 hour) derived from this pharmacokinetic (PK)<br />

evaluation of IV busulfan is 1,100 mcmol*min. AUC results >1,500 mcmol*min are associated with<br />

hepatic veno-occlusive disease. A dose reduction should be considered before the next busulfan infusion.<br />

AUC results

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!